Please login to the form below

Not currently logged in
Email:
Password:

Akynzeo

This page shows the latest Akynzeo news and features for those working in and with pharma, biotech and healthcare.

Merck plans expanded filing for Emend this year

Merck plans expanded filing for Emend this year

Generics aside, competition is building in the CINV sector. Last October the FDA approved Eisai's combination Akynzeo (netupitant and palonosterol), while Tesaro's oral and injectable NK1 antagonist rolapitant was

Latest news

  • Eisai wins US approval for chemotherapy side effects drug Eisai wins US approval for chemotherapy side effects drug

    Combined, these studies involved 1, 720 people receiving chemotherapy, with groups split between those taking Akynzeo and those on Aloxi. ... For Akynzeo the figures were 90.4% and 80.6% respectively, while for the Aloxi arm the figures were 80.1% and

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics